	US 11,786,558 B2
	Methods of cell therapies
Erik J. Woods, Carmel, IN (US); Brian H. Johnstone, Fishers, IN (US); Dongsheng Gu, Indianapolis, IN (US); Aubrey Marie Sherry, Carmel, IN (US); Kelsey Gwen Musall, Avon, IN (US); Megan Sykes, New York, NY (US); Tomoaki Kato, New York, NY (US); and Jianing Fu, New York, NY (US)
Assigned to Ossium Health, Inc., San Francisco, CA (US)
Filed by Ossium Health, Inc., San Francisco, CA (US)
Filed on Mar. 16, 2022, as Appl. No. 17/696,779.
Application 17/696,779 is a continuation of application No. PCT/US2021/064152, filed on Dec. 17, 2021.
Claims priority of provisional application 63/127,949, filed on Dec. 18, 2020.
Prior Publication US 2022/0241342 A1, Aug. 4, 2022
Int. Cl. A61K 35/28 (2015.01); A61P 37/06 (2006.01); A61K 35/38 (2015.01); A61K 31/436 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); C12N 5/0783 (2010.01); C12N 5/0789 (2010.01)

CPC A61K 35/28 (2013.01) [A61K 31/436 (2013.01); A61K 35/17 (2013.01); A61K 35/38 (2013.01); A61K 38/1774 (2013.01); A61P 37/06 (2018.01); C12N 5/0636 (2013.01); C12N 5/0647 (2013.01)]

20 Claims

1. A method of establishing a mixed chimerism, establishing a T-cell macrochimerism of at least about 4%, preventing a host-versus-graft response, and/or preventing a rejection of a donor organ in a subject that has received an organ transplant, wherein said donor organ comprises an intestine and wherein said organ transplant comprises an intestinal transplant (“ITx”), the method comprising:

a) generating a lymphohematopoietic graft-versus-host response (“LGVHR”) in the subject; and

b) upon generation of said LGVHR, administering to said subject a population of CD34+ cells, wherein said population of CD34+ cells is selected for such that said population of CD34+ cells comprises no more than about 1×10⁴CD3+ cells per kilogram of said subject.